PT103069A - Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacina - Google Patents
Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacinaInfo
- Publication number
- PT103069A PT103069A PT103069A PT10306904A PT103069A PT 103069 A PT103069 A PT 103069A PT 103069 A PT103069 A PT 103069A PT 10306904 A PT10306904 A PT 10306904A PT 103069 A PT103069 A PT 103069A
- Authority
- PT
- Portugal
- Prior art keywords
- administration
- pharmaceutical form
- reduced toxicity
- indometacin
- oral
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT103069A PT103069A (pt) | 2004-02-10 | 2004-02-10 | Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacina |
PCT/PT2005/000003 WO2005074992A1 (en) | 2004-02-10 | 2005-02-09 | Pharmaceutical form of reduced toxicity for oral administration of indomethacin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT103069A PT103069A (pt) | 2004-02-10 | 2004-02-10 | Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacina |
Publications (1)
Publication Number | Publication Date |
---|---|
PT103069A true PT103069A (pt) | 2005-08-31 |
Family
ID=34836915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT103069A PT103069A (pt) | 2004-02-10 | 2004-02-10 | Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacina |
Country Status (2)
Country | Link |
---|---|
PT (1) | PT103069A (pt) |
WO (1) | WO2005074992A1 (pt) |
-
2004
- 2004-02-10 PT PT103069A patent/PT103069A/pt not_active Application Discontinuation
-
2005
- 2005-02-09 WO PCT/PT2005/000003 patent/WO2005074992A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2005074992A1 (en) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1940467T3 (da) | Lægemiddelsammensætning med langvarig frigivelse | |
BRPI0616703A2 (pt) | forma de dosagem farmacêutica | |
NO20075628L (no) | Farmasøytiske formuleringer | |
ATE532788T1 (de) | Pharmazeutische verbindungen | |
BRPI0810646A2 (pt) | " compostos farmacêuticos ". | |
RU2398586C3 (ru) | Фармацевтическая композиция | |
ITBO20050123A1 (it) | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina | |
FR2881652B1 (fr) | Forme pharmaceutique orale microparticulaire anti-mesuage | |
FR2892937B1 (fr) | Forme pharmaceutique orale microparticulaire anti-mesusage | |
BRPI0511900A (pt) | composições farmacêuticas | |
IL191907A0 (en) | Azepinoindole derivatives as pharmaceutical agents | |
NO20053119D0 (no) | Farmasoytiske sarmmensetninger med fentanyl for intranasal administrasjon. | |
PL1957073T3 (pl) | Substancja lecznicza | |
ITMO20050343A1 (it) | Supporto per medicazione | |
BRPI0719880A2 (pt) | Forma de dosagem sólida farmacêutica para administração oral e método para preparar a mesma. | |
ATE483702T1 (de) | Neue pharmazeutische verbindungen | |
BRPI0812964A2 (pt) | Forma de dosagem farmacêutica oral sólida | |
EP1941896A4 (en) | COMPOSITION CONTAINING A DIPEPTIDE FOR ORAL ADMINISTRATION | |
FI20041129A0 (fi) | Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi | |
BRPI0918539A2 (pt) | preparação farmacêutica sólida para administração oral | |
HUP0500683A3 (en) | New arylpiprazole salts for producing pharmaceutical composition | |
ITMI20051826A1 (it) | Kit per la somministrazione parenterale di medicamenti | |
HK1092734A1 (en) | Oral formulation for twice-daily administration | |
ITMI20041447A1 (it) | Composizione farmaceutica comprendente gabapentina | |
PT103069A (pt) | Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BB1A | Laying open of patent application |
Effective date: 20040415 |
|
MM3A | Annulment or lapse |
Effective date: 20060810 |
|
NF3A | Restitutio in integrum |
Free format text: RESTITUTIO IN INTEGRUM Effective date: 20070302 |
|
FC3A | Refusal |
Effective date: 20070615 |